Luisa Schnobrich

Ms. Luisa Schnobrich

Universitätsklinikum Regensburg
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Christina PfabChristina Pfab
Christina Pfab
Luisa SchnobrichLuisa Schnobrich
Luisa Schnobrich
Samir EldanasourySamir Eldanasoury
Samir Eldanasoury
AGAndré Gessner
André Gessner
Nahed El NajjarNahed El Najjar
Nahed El Najjar
The substantial costs of clinical trials, the lengthy timelines of new drug discovery and development, along the high attrition rates underscore the need for alternative strategies for finding quickly suitable therapeutics agents. Given that most approved drugs possess more than one target tightly linked to other diseases, it encourages promptly testing these drugs in patients. Over the past decades, this has led to considerable attention for drug repurposing, which relies on identifying new uses for approved or investigational drugs outside the scope of the original medical indication. The known safety of approved drugs minimizes the possibility of failure for adverse toxicology, making them attractive de-risked compounds for new applications with potentially lower overall development costs and shorter development timelines. This latter case is an exciting opportunity, specifically in oncology, due to increased resistance towards the current therapies. Indeed, a large body of evidence shows that a wealth of non-cancer drugs has beneficial effects against cancer. Interestingly, 335 drugs are currently being evaluated in different clinical trials for their potential activities against various cancers (Redo database). This review aims to provide an extensive discussion about the anti-cancer activities exerted by antimicrobial agents and presents information about their mechanism(s) of action and stage of development/evaluation.

17 June 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
Luisa SchnobrichLuisa Schnobrich
Luisa Schnobrich
HCHayo Castrop
Hayo Castrop
Chronic kidney disease (CKD) is a growing concern in aging populations. CKD is characterized by two hallmark symptoms: a decline in the glomerular filtration rate (GFR) and albuminuria. Early changes in kidney function are notoriously underdiagnosed, suggesting the need for new noninvasive diagnostic and prognostic biomarkers of CKD. Thus, analysis of urinary extracellular vesicles (uEVs) may broaden the diagnostic options for CKD. EVs are a heterogeneous group of particles, enclosed by a lipid bilayer, which differ in size, biogenesis, and function. EVs can be readily recovered from the urine (urinary EVs, uEVs), where they are derived from various cells of the kidney, bladder, prostate, and utero-vaginal tract. Within the kidney, EVs are released by almost all cell types, including but not limited to podocytes, cells of the proximal and distal tubules, the collecting duct, and the loop of Henle. In addition to specific markers of parental cells, uEVs carry mRNAs, miRNAs, and proteins. Thus, analysis of uEVs may provide insights into the content and composition of the specific cells from which they are released, leading to the identification of new diagnostic and prognostic biomarkers for kidney diseases of different etiologies. This review provides an overview of kidney disease-related changes in uEV size and concentration and covers the potential of uEVs as new biomarkers for various types of kidney disease.